[Treatment of postmenopausal osteoporosis with raloxifene].
The authors present the results of the international multicentric clinical study (MORE--The Multiple Outcomes of Raloxifen Evaluation) of postmenopausal osteoporosis by raloxifen, participated by the authors. The evaluation of MORE indicated that raloxifen represents another further significant possibility of the treatment of postmenopausal osteoporosis by increasing bone density of vertebrae and femoral neck, and reducing the risk of vertebral fractures.
Fedelesova
V
V
Klinika farmakoterapie Ustavu preventívnej a klinickej medicíny a FNsP akademika L. Dérera v Bratislave.
Chylova
K
K
Dzurik
D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D004965:Estrogen Antagonists; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride